The lifetable approach to estimate the life-expectancy of T2DM patients used a weak assumption on the continuum risk profiles by age group. To improve transparency and accuracy of lifetable estimation, this study aimed to use a microsimulation modeling approach to produce the life-expectancy of T2DM patients. We used the National Health and Nutrition Examination Survey (2011-2012) and linked the National Death Index to calibrate the mortality equation of the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model, a person-level discrete-time microsimulation model, which has been extensively validated against 18 international trials before. Life expectancy was estimated under two treatment targets: population average: A1c 7.5%, SBP 130 mmHg, LDL 100 mg/dl, and BMI 30 kg/m2; recommended level: A1c 6.5%, SBP 120 mmHg, LDL 90 mg/dl, and BMI 25 kg/m2. Table 1 presents the life-expectancies of patients with type 2 diabetes by subgroups. Females in general lives 4 years longer than males, while racial-ethnic difference in life-expectancy was not significant among T2DM patients, conditional on the trajectories of risk factors across groups. The recommended goal of biomarkers prolongs life expectancy by 1.3-1.8 years, compared with the current population average. The new approach may generate more accurate statistics for national diabetes surveillance.


H. Kianmehr: None. S. Yang: None. V. Fonseca: Consultant; Self; Abbott, Asahi Kasei Corporation, AstraZeneca, Bayer Inc., Novo Nordisk Inc., Sanofi. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc. Stock/Shareholder; Self; Amgen, Bravo4health. L. Shi: None. J.D. Brown: None. Y. Guo: None. H. Shao: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at